The predictable effect that renal failure has on H2 receptor antagonists—increasing the half-life along with increasing prescribing errors

Butler PC. b-cell deficit and increased b-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102–110 29. Vives-Pi M, Somoza N, Fernandez-Alvarez J et al. Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MN-2 and of sensitivity to endotoxin (LPS) in islet b cells. Clin Exp Immunol 2003; 133: 208–218 30. Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 2004; 14: 5–8 31. Dengler TJ, Raftery MJ, Werle M, Zimmermann R, Schonrich G. Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1b. Transplantation 2000; 69: 1160–1168 32. Hohmeier HE, Tran VV, Chen G, Gasa R, Newgard CB. Inflammatory mechanisms in diabetes: lessons from the b-cell. Int J Obes Relat Metab Disord 2003; 27: S12–S16 33. Yurochko AD, Huang E-S. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol 1999; 162: 4806–4816 34. Movahedi B, van de Casteele M, Caluwé N et al. Human pancreatic duct cells can produce tumour necrosis factor-a that damages neighbouring beta cells and activates dendritic cells. Diabetologia 2004; 47: 998–1008 35. Rentenaar RJ, Gamadia LE, van DerHoek N et al. Development of virus-specific CD4þ T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105: 541–548 36. Essa S, Raghupathy R, Pacsa AS, El-Shazly A, Said T. Changes in cell-mediated immunity in kidney transplant recipients with active CMV infection. FEMS Immunol Med Microbiol 2002; 32: 199–204 37. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462–1470 38. Koetz AC, Delbruck R, Furtwangler A et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, doubleblind, placebo-controlled study. Transplantation 2001; 72: 1325–1327 39. Sagedal S, Nordal KP, Hartmann A et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899–1908 40. Liu CL, Fan ST, Lo CM et al. Interleukin-2 receptor antibody (Basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transplant 2004; 10: 728–733